Pulmonary hypertension in interstitial lung disease
Open Access
- 5 March 2008
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 31 (6), 1357-1367
- https://doi.org/10.1183/09031936.00171307
Abstract
In the lungs, parenchymal and vascular remodelling share pathomechanisms that may explain the relatively high prevalence (30–40%) of pulmonary hypertension (PH) in interstitial lung disease (ILD) patients. Notably, PH significantly contributes to exercise limitation and dismal prognosis of ILD patients. The absence of specific clinical symptoms commonly leads to delayed diagnosis. Besides clinical judgment and out-of-proportion reduction in diffusing capacity, severe hypoxaemia or exercise oxygen desaturation, echocardiography and biomarkers such as B-type natriuretic peptide (BNP) and N-terminal pro-hormone BNP are potentially helpful tools in identifying PH. However, right heart catheterisation is still necessary to confirm the diagnosis. Management of PH in ILD comprises treatment of the underlying disease process and long-term oxygen therapy. Affected patients should be listed for lung transplantation without delay, when appropriate. However, due to age and comorbidities only a minority of ILD patients will be eligible for lung transplantation. In the absence of satisfactory therapies for many ILDs, and considering the clinical burden of PH in affected patients, specific vasomodulatory therapies presently approved for PAH may be promising options for ILD patients. Consequently, there is an urgent need for adequately designed clinical trials to assess the effectiveness of specific PH therapy in the context of ILDs.Keywords
This publication has 100 references indexed in Scilit:
- Prediction of pulmonary hypertension in idiopathic pulmonary fibrosisRespiratory Medicine, 2007
- Endothelin-1 Induces Alveolar Epithelial–Mesenchymal Transition through Endothelin Type A Receptor–Mediated Production of TGF-β1American Journal of Respiratory Cell and Molecular Biology, 2007
- NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potentialNature Reviews Drug Discovery, 2006
- Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular RemodelingCirculation, 2006
- Contraindications and Safety of Transbronchial Lung Biopsy via Flexible BronchoscopyRespiration, 2005
- Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristicsEuropean Respiratory Journal, 2005
- Impact of Recipient Age and Procedure Type on Survival After Lung Transplantation for Pulmonary FibrosisThe Annals of Thoracic Surgery, 2005
- Clinical classification of pulmonary hypertensionJournal of the American College of Cardiology, 2004
- The Mouse Through the Looking GlassCirculation Research, 2004
- Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation.Cell Metabolism, 1984